MCID: LYM019
MIFTS: 47

Lymphosarcoma

Categories: Immune diseases, Rare diseases

Aliases & Classifications for Lymphosarcoma

MalaCards integrated aliases for Lymphosarcoma:

Name: Lymphosarcoma 52 54
Lymphoma, Diffuse 71
Lymphoma 71

Classifications:



External Ids:

UMLS 71 C0024299 C3714542

Summaries for Lymphosarcoma

MalaCards based summary : Lymphosarcoma, also known as lymphoma, diffuse, is related to reticulum cell sarcoma and follicular lymphoma. An important gene associated with Lymphosarcoma is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are Immune response Fc epsilon RI pathway and Chromatin Regulation / Acetylation. The drugs Ferrous succinate and Tropisetron have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are Reduced mammosphere formation and cardiovascular system

Wikipedia : 74 Lymphoma is a group of blood cancers that develop from lymphocytes (a type of white blood cell). The... more...

Related Diseases for Lymphosarcoma

Diseases related to Lymphosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 336)
# Related Disease Score Top Affiliating Genes
1 reticulum cell sarcoma 30.8 TNFRSF8 PTPRC
2 follicular lymphoma 29.7 IGH BCL6 BCL2
3 lymphoblastic lymphoma 29.4 TNFRSF8 PTPRC BCL6
4 immune deficiency disease 29.1 TNFRSF8 PTPRC ERVW-1 BCL6
5 reticulosarcoma 29.0 TNFRSF8 PTPRC IGH BCL6 BCL2
6 hodgkin's lymphoma, lymphocytic-histiocytic predominance 29.0 TNFRSF8 PTPRC BCL6
7 myeloma, multiple 28.8 TNFRSF8 PTPRC CD22 BCL6
8 mantle cell lymphoma 28.8 PTPRC IGH BCL6 BCL2
9 leukemia, acute lymphoblastic 28.8 PTPRC NR3C1 IGH CD22 BCL6 BCL2
10 peripheral t-cell lymphoma 28.7 TNFRSF8 PTPRC DNMT3A BCL6
11 leukemia, chronic myeloid 28.6 PTPRC G6PD DNMT1 BCL2
12 burkitt lymphoma 28.4 TNFRSF8 DNMT1 CD22 BCL6 BCL2
13 lymphoma, hodgkin, classic 28.4 TNFRSF8 PTPRC BCL6 BCL2
14 leukemia, chronic lymphocytic 28.1 TNFRSF8 PTPRC IGH DNMT3A CD22 BCL6
15 leukemia, acute myeloid 28.0 TNFRSF8 PTPRC DNMT3A DNMT1 CD22 BCL6
16 b-cell lymphoma 27.9 TNFRSF8 PTPRC IGH CD22 BCL6 BCL2
17 leukemia 10.7
18 lymphocytic leukemia 10.5
19 lymphoma 10.5
20 sarcoma 10.5
21 spindle cell sarcoma 10.5
22 acute leukemia 10.4
23 trimethoprim allergy 10.4 GSR G6PD
24 meningococcal infection 10.3 GSR G6PD
25 eye lymphoma 10.3 CD22 BCL6
26 diarrhea 10.2
27 parotitis 10.2 H6PD G6PD
28 pancreas lymphoma 10.2 PTPRC BCL6
29 epiglottis neoplasm 10.2 PTPRC BCL6
30 heart lymphoma 10.2 PTPRC BCL6
31 ataxia and polyneuropathy, adult-onset 10.2
32 neutropenia 10.2
33 hemolytic anemia 10.2
34 peritonitis 10.2
35 myeloid leukemia 10.2
36 posttransplant acute limbic encephalitis 10.2
37 plasmablastic lymphoma 10.1 PTPRC BCL6
38 intussusception 10.1
39 mycosis fungoides 10.1
40 deficiency anemia 10.1
41 hypereosinophilic syndrome 10.1
42 hypoglycemia 10.1
43 splenomegaly 10.1
44 nodal marginal zone b-cell lymphoma 10.1 BCL6 BCL2
45 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.1 BCL6 BCL2
46 yemenite deaf-blind hypopigmentation syndrome 10.1
47 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.1
48 uveitis 10.1
49 thrombocytopenia 10.1
50 fibrosarcoma 10.1

Graphical network of the top 20 diseases related to Lymphosarcoma:



Diseases related to Lymphosarcoma

Symptoms & Phenotypes for Lymphosarcoma

GenomeRNAi Phenotypes related to Lymphosarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 BCL6 CD22 CTSL DNMT3A NR3C1 PTPRC

MGI Mouse Phenotypes related to Lymphosarcoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.92 BCL2 BCL6 DNMT3A G6PD GSR NR3C1
2 cellular MP:0005384 9.91 BCL2 BCL6 CD22 DNMT1 DNMT3A G6PD
3 endocrine/exocrine gland MP:0005379 9.76 BCL2 BCL6 DNMT3A H6PD NR3C1 PTPRC
4 hematopoietic system MP:0005397 9.65 BCL2 BCL6 CD22 DNMT1 DNMT3A G6PD
5 immune system MP:0005387 9.28 BCL2 BCL6 CD22 DNMT1 DNMT3A NR3C1

Drugs & Therapeutics for Lymphosarcoma

Drugs for Lymphosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 882)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ferrous succinate Approved Phase 4 10030-90-7
2
Tropisetron Approved, Investigational Phase 4 89565-68-4, 105826-92-4 5595
3
Clarithromycin Approved Phase 4 81103-11-9 84029
4
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
5
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
6
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
7
Sodium citrate Approved, Investigational Phase 4 68-04-2
8
Fosaprepitant Approved Phase 4 172673-20-0 219090
9
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
10
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
11
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
12
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
13
Palonosetron Approved, Investigational Phase 4 119904-90-4, 135729-61-2, 135729-56-5 148211
14
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
15
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
16
Protein C Approved Phase 4
17
Nitric Oxide Approved Phase 4 10102-43-9 145068
18
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
19
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
20
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
21
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
22
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
23
Potassium citrate Approved, Investigational, Vet_approved Phase 4
24
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
25
Morphine Approved, Investigational Phase 4 57-27-2 5288826
26
Nicotine Approved Phase 4 54-11-5 942 89594
27
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
28
Lithium carbonate Approved Phase 4 554-13-2
29
Infliximab Approved Phase 4 170277-31-3
30
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
31
Prilocaine Approved Phase 4 721-50-6 4906
32
Teniposide Approved Phase 4 29767-20-2 34698
33
Ofloxacin Approved Phase 4 82419-36-1 4583
34
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
35
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
36
Epirubicin Approved Phase 4 56420-45-2 41867
37
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
38
Docetaxel Approved, Investigational Phase 4 114977-28-5 148124
39
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
40
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
41
Glucagon Approved Phase 4 16941-32-5
42
Liraglutide Approved Phase 4 204656-20-2 44147092
43
Sargramostim Approved, Investigational Phase 4 83869-56-1, 123774-72-1
44
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
45
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
46
Ribavirin Approved Phase 4 36791-04-5 37542
47
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
48
Zidovudine Approved Phase 4 30516-87-1 35370
49
Methoxsalen Approved Phase 4 298-81-7 4114
50
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311

Interventional clinical trials:

(show top 50) (show all 7105)
# Name Status NCT ID Phase Drugs
1 A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
2 Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT03010579 Phase 4 erythropoietin;iron supplementation
3 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
4 First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents Unknown status NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
5 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage Ⅲ/Ⅳ NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501149 Phase 4 DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase);Modified SMILE (MTX,DEX,IFO,L-ASP,Etoposide,Mesna)
6 A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy Unknown status NCT02585947 Phase 4 Tenofovir
7 Comparison of Methotrexate Versus Interferon-alfa 2b on Efficacy, Safety and Quality of Life in Patients With Primary Cutaneous T-cell Lymphomas Unknown status NCT02323659 Phase 4 Methotrexate;Interferon Alfa-2b
8 Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy Unknown status NCT01768195 Phase 4 Entecavir prophylaxis
9 Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma Unknown status NCT01765231 Phase 4 Entecavir prophylaxis;Observation arm
10 A Single Center Randomized Controlled Trial of the Efficacy and Safety of PEG-rhG-CSF After Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Patients Unknown status NCT02905942 Phase 4 PEG-rhG-CSF;rhG-CSF
11 A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage I/II NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) Unknown status NCT01501136 Phase 4
12 Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors Unknown status NCT02929615 Phase 4
13 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
14 Evaluation of the Immune Response After Vaccination Against Hepatitis B in Patients With Indolent Lymphoproliferative Disorders With no Treatment. Unknown status NCT01698866 Phase 4
15 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
16 Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
17 Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
18 German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
19 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
20 A Multi-central Perspective Randomized Controlled Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation Unknown status NCT02576327 Phase 4 Tropisetron;Dexamethasone;Aprepitant
21 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
22 Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH) Unknown status NCT02347878 Phase 4 Aprepitant
23 Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
24 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
25 The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
26 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
27 Study of the Relationship Between the Rate of Residual Platinum in the Blood and the Incidence of Persistent Neurotoxicity in Patients Treated for Gastrointestinal Cancer With Oxaliplatin Unknown status NCT00274885 Phase 4 oxaliplatin
28 Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice Unknown status NCT01273441 Phase 4 PPI, amoxicillin, metronidazole and clarithromycin;PPI, amoxicillin, metronidazole and clarithromycin
29 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
30 A Phase 4, Randomized, Open-Label Study to Assess Humoral and Intestinal Polio Immunity Following a Three-Dose Trivalent Inactivated Polio Vaccine Schedule Relative to Two Sequential Schedules of IPV/Bivalent Oral Polio Vaccines Unknown status NCT01841671 Phase 4
31 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
32 The Multi-center,Open-label,Single Arm Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy Completed NCT02805218 Phase 4 PEG-rhG-CSF
33 A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA Completed NCT01180049 Phase 4 temsirolimus;temsirolimus
34 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
35 A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens Completed NCT00090038 Phase 4 rituximab
36 HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
37 A Study to Evaluate the Safety of MabThera (Rituximab) Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma Who Have Responded to Induction Therapy. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
38 Open Label Study of ONTAK® (Denileukin Diftitox, DAB389IL-2) to Estimate Response in Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status Completed NCT00211198 Phase 4 ONTAK (denileukin difitox, DAB389IL-2)
39 Phase IV Randomized Study of Two Dose Levels of Targretin® Capsules in Subjects With Refractory Cutaneous T-Cell Lymphoma Completed NCT01007448 Phase 4 Bexarotene
40 Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1) Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
41 A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25 Completed NCT00051012 Phase 4 ONTAK
42 A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25 Completed NCT00050999 Phase 4 ONTAK
43 A Randomized Controlled Multi-center Clinical Trial on Treatment of Peripheral T-cell Lymphoma With DGPT Regiment (Gemcitabine,Cisplatin,Prednisone ,Thalidomide ) Completed NCT01664975 Phase 4 GDPT regimen;CHOP regimen
44 Apatinib for Relapsed and Refractory Difuse Large B Cell Lymphoma: an Open-label, Single Armed, Exploratory Study Completed NCT03376958 Phase 4 Apatinib
45 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
46 A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
47 Estimation of Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene Treatment of Cutaneous T Cell Lymphoma - Pilote Study Completed NCT01569724 Phase 4
48 Zevalin® (Ibritumomab Tiuxetan) Followed by Rituxan® (Rituximab) Maintenance in Previously Treated Low Grade Non-Hodgkin’s Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)
49 Expanded Access Program of Pegfilgrastim in Patients With Non-Hodgkin Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
50 The Multi-centers Trial for Patients With Non-Hodgkin's Lymphoma to Assess the Protective Effect of Valsartan on Chronic Cardiotoxicity Induced by CHOP Completed NCT00162955 Phase 4 Valsartan

Search NIH Clinical Center for Lymphosarcoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ASPARAGINASE
Cytarabine
Cytarabine liposome
irinotecan
Irinotecan hydrochloride
Mitoxantrone
Mitoxantrone Hydrochloride
Thiotepa

Genetic Tests for Lymphosarcoma

Anatomical Context for Lymphosarcoma

MalaCards organs/tissues related to Lymphosarcoma:

40
B Cells, T Cells, Bone, Lung, Bone Marrow, Myeloid, Breast

Publications for Lymphosarcoma

Articles related to Lymphosarcoma:

(show top 50) (show all 4204)
# Title Authors PMID Year
1
Suppression of metallothionein-I/II expression and its probable molecular mechanisms. 54 61
12426140 2002
2
[Differential diagnostic and prognostic value of serum cytokines (soluble CD30, soluble interleukin-2 receptor, interleukin-10 and interleukin-6) in Hodgkin's disease and lymphosarcomas]. 61 54
11494447 2001
3
Foliate Lymphoid Aggregates as Novel Forms of Serous Lymphocyte Entry Sites of Peritoneal B Cells and High-Grade B Cell Lymphomas. 61
31767783 2020
4
Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use. 61
31648953 2019
5
Interferon gamma inducible protein 16 (IFI16) expression is reduced in mantle cell lymphoma. 61
31840115 2019
6
EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas. 61
31789821 2019
7
Cancer Incidence and Mortality in Firefighters: A State-of-the-Art Review and Meta-َAnalysis. 61
31759344 2019
8
Bacterial l-asparaginases for cancer therapy: Current knowledge and future perspectives. 61
30993718 2019
9
Detection and Identification of Enzootic Bovine Leukosis (EBL) in Calves in Iran. 61
31592598 2019
10
Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook. 61
30045683 2019
11
The Unsolved Puzzle of c-Rel in B Cell Lymphoma. 61
31277480 2019
12
Prevalence and clinical significance of koala retrovirus in two South Australian koala (Phascolarctos cinereus) populations. 61
31162024 2019
13
Surveillance scanning in lymphoma. 61
31437139 2019
14
Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma. 61
30795996 2019
15
Analysis of preventability of malignancy-related maternal death from the nationwide registration system of maternal deaths in Japan. 61
30999803 2019
16
Incidence of Neoplasia in Pigs and Its Relevance to Clinical Organ Xenotransplantation. 61
30909988 2019
17
Will donor-derived neoplasia be problematic after clinical pig organ or cell xenotransplantation? 61
30411396 2019
18
Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma). 61
29419530 2019
19
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. 61
30642819 2019
20
Neurolymphomatosis caused by T-cell lymphosarcoma in a cat: imaging description and treatment review. 61
30828460 2019
21
Long-term cadmium exposure enhances metallothionein-1 induction after subsequent exposure to high concentrations of cadmium in P1798 mouse lymphosarcoma cells. 61
30944283 2019
22
Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies. 61
29795433 2019
23
Isolation, Purification, Characterisation and Application of L-ASNase: A Review. 61
30318009 2019
24
Molecular Fingerprinting of Anatomically and Temporally Distinct B-Cell Lymphoma Samples by Next-Generation Sequencing to Establish Clonal Relatedness. 61
29979613 2019
25
LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation. 61
31552193 2019
26
Expression and clinical significance of neuropilin-1 in Epstein-Barr virus-associated lymphomas. 61
31282408 2019
27
An unusual cause of colic stenosis in a renal transplant recipient: primary colonic diffuse large B-cell lymphoma. 61
30737361 2019
28
Massive bone marrow necrosis revealing an HIV-related primary bone marrow lymphoma: a diagnostic challenge. 61
30293217 2019
29
Characterisation of infection associated microRNA and protein cargo in extracellular vesicles of Theileria annulata infected leukocytes. 61
30370674 2019
30
Lymphocyte proliferation and apoptosis of lymphocyte subpopulations in bovine leukemia virus-infected dairy cows with high and low proviral load. 61
30502911 2018
31
Enzyme-free digital counting of endogenous circular RNA molecules in B-cell malignancies. 61
30087459 2018
32
Sequence Variation of Epstein-Barr Virus: Viral Types, Geography, Codon Usage, and Diseases. 61
30111570 2018
33
Unusual behavior of diffuse large B-cell lymphoma as cardiac invasion with rapid spontaneous regression after fine needle aspiration cytology. 61
30476383 2018
34
Simultaneous Presence of Follicular Lymphoma, Diffuse Large B-cell Lymphoma, and Hodgkin-like Lymphoma 61
30398157 2018
35
A critical analysis of L-asparaginase activity quantification methods-colorimetric methods versus high-performance liquid chromatography. 61
30155702 2018
36
A Primary Retroperitoneal Diffuse Large B-Cell Lymphoma: A Challenging Diagnosis. 61
31123618 2018
37
[Clinicopathologic features of breast lymphoma in core needle biopsy]. 61
30317726 2018
38
Can Bovine Leukemia Virus Be Related to Human Breast Cancer? A Review of the Evidence. 61
29777406 2018
39
Dissecting aggressive B-cell lymphoma through genomic analysis - What is clinically relevant? 61
30213388 2018
40
Fluorescein sodium-guided biopsy or resection in primary central nervous system lymphomas with contrast-enhancing lesion in MRI. 61
30117022 2018
41
Long Non-Coding RNAs Guide the Fine-Tuning of Gene Regulation in B-Cell Development and Malignancy. 61
30134619 2018
42
Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma. 61
31086689 2018
43
l-Asparaginase: a feasible therapeutic molecule for multiple diseases. 61
29872609 2018
44
Comparison of Epstein-Barr virus-positive mucocutaneous ulcer associated with treated lymphoma or methotrexate in Japan. 61
29314151 2018
45
[Incidence of Bone Marrow Involvement in Different Pathological Type Lymphoma Patients]. 61
29950217 2018
46
Primary pulmonary lymphoproliferative neoplasms. 61
29697079 2018
47
Late duodenal metastasis from renal cell carcinoma with newly developed malignant lymphoma: A case report. 61
29556388 2018
48
Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. 61
29550382 2018
49
Molecular epidemiology and characterization of bovine leukemia virus in domestic yaks (Bos grunniens) on the Qinghai-Tibet Plateau, China. 61
29224130 2018
50
Genome-wide scan for commons SNPs affecting bovine leukemia virus infection level in dairy cattle. 61
29439661 2018

Variations for Lymphosarcoma

Expression for Lymphosarcoma

Search GEO for disease gene expression data for Lymphosarcoma.

Pathways for Lymphosarcoma

GO Terms for Lymphosarcoma

Cellular components related to Lymphosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 replication fork GO:0005657 8.62 DNMT1 BCL6

Biological processes related to Lymphosarcoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.89 SMARCA4 NR3C1 DNMT3A DNMT1 BCL6
2 chromatin organization GO:0006325 9.78 SMARCA4 NR3C1 DNMT3A DNMT1
3 negative regulation of cell growth GO:0030308 9.63 SMARCA4 BCL6 BCL2
4 regulation of gene expression GO:0010468 9.62 PTPRC DNMT3A DNMT1 BCL2
5 response to gamma radiation GO:0010332 9.54 PTPRC BCL2
6 B cell differentiation GO:0030183 9.54 PTPRC BCL6 BCL2
7 negative regulation of reactive oxygen species metabolic process GO:2000378 9.52 G6PD BCL2
8 DNA methylation GO:0006306 9.51 DNMT3A DNMT1
9 pentose-phosphate shunt GO:0006098 9.43 H6PD G6PD
10 NADP metabolic process GO:0006739 9.4 H6PD G6PD
11 DNA methylation involved in embryo development GO:0043045 9.26 DNMT3A DNMT1
12 C-5 methylation of cytosine GO:0090116 9.16 DNMT3A DNMT1
13 positive regulation of B cell proliferation GO:0030890 9.13 PTPRC BCL6 BCL2
14 DNA methylation on cytosine GO:0032776 8.62 DNMT3A DNMT1

Molecular functions related to Lymphosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 NADP binding GO:0050661 9.33 H6PD GSR G6PD
2 oxidoreductase activity, acting on CH-OH group of donors GO:0016614 9.32 H6PD G6PD
3 DNA-methyltransferase activity GO:0009008 9.26 DNMT3A DNMT1
4 DNA (cytosine-5-)-methyltransferase activity GO:0003886 8.96 DNMT3A DNMT1
5 glucose-6-phosphate dehydrogenase activity GO:0004345 8.62 H6PD G6PD

Sources for Lymphosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....